Vinva Investment Management Ltd Acquires 122,959 Shares of Pfizer Inc. $PFE

Vinva Investment Management Ltd raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 46.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 390,489 shares of the biopharmaceutical company’s stock after buying an additional 122,959 shares during the period. Vinva Investment Management Ltd’s holdings in Pfizer were worth $9,446,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the stock. Te Ahumairangi Investment Management Ltd lifted its position in Pfizer by 16.2% during the second quarter. Te Ahumairangi Investment Management Ltd now owns 249,046 shares of the biopharmaceutical company’s stock worth $6,037,000 after acquiring an additional 34,650 shares during the last quarter. Thornburg Investment Management Inc. lifted its holdings in Pfizer by 5.7% during the 2nd quarter. Thornburg Investment Management Inc. now owns 10,458,571 shares of the biopharmaceutical company’s stock worth $253,516,000 after purchasing an additional 562,798 shares during the last quarter. Employees Retirement System of Texas bought a new stake in Pfizer in the 2nd quarter valued at $1,711,000. Choreo LLC grew its holdings in Pfizer by 3.2% in the 2nd quarter. Choreo LLC now owns 181,463 shares of the biopharmaceutical company’s stock valued at $4,399,000 after buying an additional 5,664 shares in the last quarter. Finally, Northwest & Ethical Investments L.P. increased its position in Pfizer by 192.2% during the 2nd quarter. Northwest & Ethical Investments L.P. now owns 611,943 shares of the biopharmaceutical company’s stock worth $14,833,000 after buying an additional 402,490 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $25.72 on Thursday. The firm’s 50 day simple moving average is $24.94 and its 200 day simple moving average is $24.55. The firm has a market capitalization of $146.21 billion, a price-to-earnings ratio of 13.68, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent research reports. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Guggenheim boosted their price objective on shares of Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a report on Monday. Morgan Stanley decreased their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.39.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.